A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer.
Latest Information Update: 20 Jul 2022
Price :
$35 *
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 07 Jun 2022 Results (n=461) of an analysis assessing predictive score to identify patients who are likely to benefit from Panitumumab treatment between differential variables subgroups using data from three clinical studies: NCT00364013, NCT00339183 and NCT00113763 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 24 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (13 Sep 2010)
- 12 Sep 2017 Secondary pooled analysis of data from two clinical trials (NCT00339183 and NCT00364013) presented at the 42nd European Society for Medical Oncology Congress.